U.S. Markets close in 1 hr 47 mins
  • S&P 500

    4,417.38
    +5.59 (+0.13%)
     
  • Dow 30

    35,116.99
    +55.44 (+0.16%)
     
  • Nasdaq

    14,830.07
    -6.92 (-0.05%)
     
  • Russell 2000

    2,210.96
    +1.31 (+0.06%)
     
  • Crude Oil

    71.98
    -0.09 (-0.12%)
     
  • Gold

    1,798.10
    -3.70 (-0.21%)
     
  • Silver

    25.29
    +0.06 (+0.23%)
     
  • EUR/USD

    1.1815
    +0.0044 (+0.3781%)
     
  • 10-Yr Bond

    1.2730
    -0.0130 (-1.01%)
     
  • Vix

    18.12
    +0.92 (+5.35%)
     
  • GBP/USD

    1.3818
    +0.0064 (+0.4643%)
     
  • USD/JPY

    110.3370
    -0.1730 (-0.1566%)
     
  • BTC-USD

    39,404.30
    +5,010.86 (+14.57%)
     
  • CMC Crypto 200

    936.76
    +21.27 (+2.32%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, May 24, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company will host a conference call and live webcast on Wednesday, May 29, 2019, at 8:30 A.M. ET to report its fourth quarter and fiscal year 2019 financial and operating results.

Those interested in participating in the conference call with the Tyme management team should dial: (877) 705-6003 (Domestic) / (201) 493-6725 (International); and enter conference code: 13691057. The call will also be available via webcast, which can be accessed through the “Investors” tab of the company’s website (ir.tymeinc.com). A replay of this conference call will be available via webcast shortly after the event.

About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 13, 2018, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com